Navigation Links
ULURU Inc. Announces Appointment of Jeffrey A. Niezgoda, M.D., as Chairman of Scientific Advisory Board
Date:3/13/2009

ADDISON, Texas, March 13 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today announced the appointment of Jeffrey A. Niezgoda, MD, FACHM, FACEP, FAPWCA as Chairman of the Company's Scientific Advisory Board.

Currently, Dr. Jeffrey Niezgoda is the Medical Director of The Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy, St. Luke's Medical Center, Aurora Health Care, in Milwaukee, Wisconsin. He also serves as the President and Chief Operating Officer of Hyperbaric & Wound Care Associates, a medical specialty group serving Southeastern Wisconsin and Northern Illinois, and as the President of the American College of Hyperbaric Medicine. Dr. Niezgoda is a nationally recognized wound care expert and has served as faculty at both national as well as international conferences. He has participated on multiple Expert Consensus Panels and has appeared before Medicare and Medicaid Services as a wound care consultant.

Renaat Van den Hooff, President & CEO of ULURU Inc. commented, "We are delighted that Dr. Niezgoda has accepted this important role with the Company. His extensive experience with Altrazeal(TM) has been invaluable and as Chairman of the Scientific Advisory Board, Dr. Niezgoda will help us to accelerate our clinical development and Altrazeal(TM) product development program."

Altrazeal(TM), a transforming powder dressing, is suitable for exuding wounds such as burns, abrasions, trauma, skin graft donor sites, surgical wounds, along with chronic, slow-healing wounds, such as diabetic foot ulcers and venous ulcers. Altrazeal(TM) is an innovative breakthrough, designed for greater effectiveness in wound closure by promoting an optimal moist wound healing environment, reducing pain, enhancing patient comfort, ease of application and removal and typically not requiring a secondary dressing.

Dr. Jeffrey A. Niezgoda stated, "I continue to be impressed wi
'/>"/>

SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
9. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
10. ULURU Inc. Reports First Quarter 2008 Financial Results
11. ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... York (PRWEB) May 21, 2013 The ... Conserve hip replacement lawsuits in U.S. District ... in response to a request from Plaintiffs’ Counsel to ... Defendant. The May 17th Order grants that request, ... be conducted. (In re: Wright Medical Technology, Inc., Conserve ...
(Date:5/21/2013)... MedMar Healing Center announces their participation ... Food Bank. Twenty-eight businesses, including MedMar Healing Center, doctors, and ... The goal is to raise food to help area kids ... families in recent years. , “We like being able ... need,” explains Douglas Chloupek of MedMar Healing Center. “Taking part ...
(Date:5/21/2013)... Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers ... disease (IBD), which could help with earlier diagnosis and ... , This finding, the first of its kind and ... via podium presentation by staff from Walter Reed National ... held May 18-21 in Orlando, Fla. , The ...
(Date:5/21/2013)... 21, 2013 Today, Zane Benefits, Inc. ... FSA accounts. Zane Benefits, which provides comprehensive and ... the leader in defined contribution and ... , According to Zane Benefits’ website, the Affordable Care ... into law in 2010 and impacts many areas of ...
(Date:5/21/2013)... May 21, 2013 The American Diabetes ... people in the United States of America are affected ... at a great risk of developing peripheral neuropathy which ... lives. The ADA further goes on saying that the ... and around 2 million new cases are diagnosed every ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2
... risk of certain types of cervical cancer. The study, ... reveals obesity and body fat //distribution are associated more ... study involved 124 women with adenocarcinoma, 139 with squamous ... control group. Adenocarcinomas involve cells from the walls of ...
... Syndrome is a severe injury to most or all of ... and often are on life support. //A new study finds ... ARDS after a trauma. ,ARDS is not a specific ... with a number of diseases including pneumonia, shock, sepsis and ...
... the larynx are diagnosed in the United States. About 5,000 ... taking away their voice box and communication, as they know ... back. ,For five years, five months and 13 days, ... forget, and that is something she says she will never ...
... who had very low birth weights are likely to ... others born at higher birth rates. //The study, conducted ... reports respiratory function is more drastically reduced with smoking ... with low birth weight, defined as weighing less than ...
... prevent bone loss may also help prevent prostate cancer from ... Kingdom indicates oral sodium clodronate may slow the spread of ... //This is a drug commonly used to prevent bone loss. ... about 85 percent of men. The researchers recruited 311 men ...
... Unlike the outbreak earlier this year, the next time ... public health systems, //says a report by the National ... chains of SARS transmission of were stopped, the virus ... to humans, the report says. ,"The wave of ...
Cached Medicine News:Health News:A voice saving surgery 2Health News:Return of SARS possible this fall 2
(Date:5/21/2013)... N.Y. , May 21, 2013 Sanofi ... (NASDAQ: REGN) today announced that the New England ... 2a study results of dupilumab (SAR231893/REGN668) in patients with ... targeting the alpha subunit of the interleukin 4 receptor ... IL-13, drivers of Th2 (Type 2 helper T cell) ...
(Date:5/21/2013)... May 21, 2013 U.S. spending on specialty ... diseases such as cancer, multiple sclerosis and rheumatoid arthritis ... end of 2015, according to a forecast released today ... http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we see ... health plans to act so they can continue to ...
(Date:5/21/2013)... CITY, Calif. , May 21, 2013 ... ACRX ), a specialty pharmaceutical company focused ... therapies for the treatment of acute and ... that in a placebo-controlled Phase 3 study ... (patient-controlled analgesia) System (NanoTab System), the primary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
... excellent choice for orthopedic procedures. ... to 24" for the surgeon's ... quickly attach to any O.R. table. ... C-Arm access and stability. Optional ...
... and ultra versatile model angulates for ... adjust the height of the support ... single post, or double tee foot. ... physician comfort and stability. A convenient ...
... torso and leg sections of ... simultaneously lift body and legs. ... raises and lowers legs individually ... A wide range of adjustment ...
... The PROfx elevates the surgical table to ... by providing the perfect table complement for ... an integral role in the surgical process, ... skill of the surgeon to minimize the ...
Medicine Products: